OpenAI 인력 이탈, 안전은 뒤로하고 20억 달러 신약 개발로
OpenAI 연구원 Miles Wang이 20억 달러 규모 AI 신약 개발 스타트업을 위해 2억 달러를 조달하며 퇴사했다. 이번 인력 유출은 벤처 캐피탈이 범용 모델에서 전문적이고 고부가가치인 바이오테크 응용 분야로 대규모로 이동하고 있음을 보여준다.
openai researcher miles wang is in talks to raise $200 million at a $2 billion valuation for a new ai drug discovery startup, with lightspeed venture partners leading the round. wang, who joined openai in 2024 after dropping out of harvard, aims to develop models that identify new uses for existing drugs to shorten the time to revenue. this exit coincides with a booming market for generative biology, chai discovery recently raised $400m at a $3.8b valuation, and isomorphic labs secured $2.1b in may. the flurry of funding indicates that while general llm development faces high costs and monetization hurdles, investors are betting heavily on ai's ability to solve expensive bottlenecks in life sciences.